ALDX insider buying and SEC filings, explained
Aldeyra Therapeutics, Inc. · CIK 1341235
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$516K
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 3, 2026 | Purchase (code P) | Todd C Brady (CEO and Director) bought 250,000 shares at about $1.67 ($418K), reported as a purchase (code P). Holdings up 17% to 1,721,298 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 5, 2026 |
| Mar 19, 2026 | Purchase (code P) | Richard Douglas (Director) bought 70,000 shares at $1.40 ($98K), reported as a purchase (code P). Holdings up 56% to 195,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 20, 2026 |
| Mar 18, 2026 | Purchase (code P) | Michael Alfieri (CFO) bought 5,000 shares at $1.42 ($7K), reported as a purchase (code P). Holdings up 200% to 7,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
8 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ALDX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.